Tirzepatide vs Survodutide
Tirzepatide is an approved dual GIP/GLP-1 receptor agonist, whilst survodutide is an investigational dual GLP-1/glucagon receptor agonist. Both enhance GLP-1 signalling but pair it with different secondary targets — GIP (tirzepatide) versus glucagon (survodutide) — resulting in overlapping yet distinct metabolic profiles.
Last updated: 2026-03-13
Tirzepatide and survodutide represent two competing strategies in the rapidly evolving field of multi-agonist metabolic therapy. Both compounds share GLP-1 receptor agonism as a core mechanism but pair it with a fundamentally different secondary receptor target, creating distinct pharmacological and clinical profiles.
Tirzepatide (Mounjaro®/Zepbound®, Eli Lilly) is a dual GIP and GLP-1 receptor agonist — the first in its class to achieve regulatory approval. Its secondary target, GIP (glucose-dependent insulinotropic polypeptide), enhances insulin secretion, may improve fat distribution, and contributes to appetite suppression through incompletely understood central mechanisms.
Survodutide (BI 456906, Boehringer Ingelheim/Zealand Pharma) is a dual GLP-1 and glucagon receptor agonist currently in Phase III trials. Its secondary target, glucagon, directly increases energy expenditure and hepatic fat oxidation — properties that may particularly benefit patients with fatty liver disease.
**Important Note:** Tirzepatide is an approved prescription medication. Survodutide is an investigational compound. This comparison is for educational purposes.
Quick Comparison Table
| Category | Tirzepatide | Survodutide |
|---|---|---|
| Drug Class | Dual GIP/GLP-1 receptor agonist | Dual GLP-1/glucagon receptor agonist |
| Developer | Eli Lilly | Boehringer Ingelheim / Zealand Pharma |
| Second Target (Beyond GLP-1) | GIP receptor (anabolic, insulinotropic) | Glucagon receptor (catabolic, thermogenic) |
| Approval Status | Approved (FDA, EMA) for T2D and obesity | Investigational — Phase III trials |
| Max Weight Loss (Trials) | ~22.5% (SURMOUNT-1, 72 weeks at 15 mg) | ~19% (Phase II, 46 weeks at 6 mg) |
| Liver Fat Reduction | Significant but indirect (secondary to weight loss) | Potentially superior — glucagon directly drives hepatic fat oxidation |
| MASH Trial Data | SYNERGY-NASH: 44-62% MASH resolution | Phase II: up to 83% MASH resolution |
| Effect on Energy Expenditure | Minimal direct effect | Glucagon increases resting energy expenditure |
Mechanism of Action: GIP vs Glucagon as the Second Target
Tirzepatide
Tirzepatide — GIP + GLP-1 Dual Agonist:
Tirzepatide is a 39-amino-acid peptide based on the native GIP sequence, engineered to also activate GLP-1 receptors. It has approximately five-fold greater affinity for GIP receptors than GLP-1 receptors.
GLP-1 Component: - Appetite suppression via hypothalamic signalling - Delayed gastric emptying - Glucose-dependent insulin secretion - Glucagon suppression in the fed state
GIP Component (Unique Differentiator): - Enhanced insulin secretion — GIP is the dominant incretin hormone in healthy individuals - Potential effects on fat tissue — GIP receptors are expressed in adipose tissue, with emerging evidence suggesting GIP signalling may influence fat distribution and lipid metabolism - Central appetite effects — GIP receptor expression in the brain suggests central appetite-modulating roles, though the exact mechanisms are still debated - Possible enhancement of beta-cell function and preservation
The GIP contribution to tirzepatide's clinical effects remains an area of active research, with debate about whether GIP receptor agonism or antagonism is the optimal approach.
Survodutide
Survodutide — GLP-1 + Glucagon Dual Agonist:
Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component counterbalances glucagon's hyperglycaemic effect, enabling safe harnessing of glucagon's catabolic properties.
GLP-1 Component: - Appetite suppression via central mechanisms - Delayed gastric emptying and enhanced satiety - Insulinotropic effects maintaining glucose homeostasis - Acts as a metabolic "brake" on glucagon's glucose-raising effect
Glucagon Component (Unique Differentiator): - Increased resting energy expenditure — glucagon stimulates hepatic thermogenesis, potentially increasing daily energy expenditure by 100-200 kcal - Direct hepatic fat oxidation — glucagon powerfully promotes fatty acid oxidation in the liver, potentially offering superior liver fat reduction and MASH resolution - Lipolysis — stimulates fat mobilisation from adipose depots - Amino acid catabolism — glucagon promotes amino acid breakdown, which theoretically could affect lean mass (mitigated by GLP-1's appetite suppression reducing overall caloric deficit) - Satiety effects — glucagon has independent satiety-promoting properties
Clinical Trial Evidence
Tirzepatide Clinical Studies
Participants: 2539
Duration: 72 weeks
Dose-dependent weight loss: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) versus 3.1% placebo. Over 50% of participants at highest dose lost ≥20% body weight.
Established tirzepatide as the most effective approved anti-obesity medication
Participants: 190
Duration: 52 weeks
MASH resolution without worsening fibrosis: 44% (5 mg), 56% (10 mg), 62% (15 mg) versus 10% placebo.
Demonstrated significant MASH benefit, though potentially lower resolution rates than survodutide Phase II data
Survodutide Clinical Studies
Participants: 387
Duration: 46 weeks
Dose-dependent weight loss of up to 19.0% at the highest dose (6 mg weekly) versus 2.8% with placebo.
Demonstrated competitive weight loss with a glucagon-inclusive mechanism
Participants: 293
Duration: 48 weeks
Up to 83% MASH resolution without worsening fibrosis at the highest dose versus 18.2% placebo.
Potentially practice-changing MASH resolution rates, leveraging glucagon's hepatic fat oxidation
Benefits Comparison
Tirzepatide Unique Benefits
- Regulatory approval — available now as a prescription medication (Mounjaro/Zepbound)
- Highest approved weight loss efficacy of any medication (~22.5% at highest dose)
- GIP component may support beta-cell function and insulin sensitivity
- Extensive clinical trial programme (SURPASS, SURMOUNT) with thousands of patients
- Established dosing, titration protocols, and safety monitoring guidelines
- Growing real-world evidence and clinical experience
Shared Benefits
- Clinically meaningful weight loss exceeding single-agonist GLP-1 therapies
- Once-weekly subcutaneous injection for convenience
- Multi-agonist approach potentially more effective than GLP-1 alone
- Improved glycaemic control in type 2 diabetes
- Reduction in cardiometabolic risk factors
- Potential liver fat reduction and MASH benefits
Survodutide Unique Benefits
- Glucagon-mediated increase in resting energy expenditure — unique thermogenic benefit
- Potentially superior liver fat reduction and MASH resolution (Phase II: 83%)
- Direct hepatic fat oxidation may benefit patients with fatty liver disease specifically
- Energy expenditure increase may aid weight loss maintenance
- Novel mechanism may benefit patients who do not respond adequately to GIP/GLP-1 agonism
Research & Evidence
Tirzepatide Research
Tirzepatide has an extensive clinical evidence base: SURPASS programme (T2D, 5 trials, ~6,000+ patients), SURMOUNT programme (obesity, 4+ trials), SYNERGY-NASH (MASH), and ongoing cardiovascular outcomes trials (SURPASS-CVOT). This represents one of the largest development programmes in metabolic medicine. Head-to-head superiority over semaglutide 1.0 mg was demonstrated in SURPASS-2.
Survodutide Research
Survodutide's evidence is currently limited to Phase II trials. The SYNCHRONIZE programme (Phase III for obesity) and MASH Phase III programme are underway. The Phase II MASH data generated exceptional excitement, but Phase III confirmation is required. No cardiovascular outcomes data exist. The evidence base will mature significantly over 2026-2028 as Phase III results emerge.
Head-to-Head Analysis
No direct comparison exists. Cross-trial inferences are limited by different trial designs, populations, and durations. A meaningful comparison will only be possible when survodutide Phase III data are available and ideally when a head-to-head trial is conducted. Until then, tirzepatide has the clear evidence advantage.
Protocol Comparison
Tirzepatide Protocol
Tirzepatide (Approved): Initiated at 2.5 mg weekly for 4 weeks, then escalated every 4 weeks: 2.5 → 5.0 → 7.5 → 10.0 → 12.5 → 15.0 mg weekly. Maintenance dose typically 5, 10, or 15 mg based on tolerability and response. Administered as a once-weekly subcutaneous injection.
This is a prescription medication requiring medical supervision.
Survodutide Protocol
Survodutide (Investigational): Phase II used dose escalation to target doses of 0.6, 2.4, 3.6, and 6.0 mg weekly. Gradual escalation used to manage GI tolerability. Once-weekly subcutaneous injection.
NOT approved for any indication. Only available through clinical trials.
Combined Use
Combining tirzepatide and survodutide would produce triple-agonist coverage (GIP + GLP-1 + glucagon), conceptually similar to retatrutide. However, such combination has not been studied and would introduce unpredictable pharmacological interactions. This approach is not recommended or supported by any evidence. Patients interested in triple agonism should monitor retatrutide's clinical development.
Safety Profiles
Tirzepatide Safety
Tirzepatide Safety (Established): Common side effects mirror GLP-1 agonists: nausea (12-33%), diarrhoea (12-21%), decreased appetite (6-11%), vomiting (5-9%), constipation (6-7%). GI effects are dose-dependent and most prominent during escalation. Slow titration is essential for tolerability. Rare: pancreatitis, gallbladder events, thyroid C-cell tumour concern (rodent, unconfirmed in humans). Contraindicated with MTC/MEN2 history. Overall safety profile comparable to GLP-1 agonists despite dual mechanism.
Survodutide Safety
Survodutide Safety (Limited): Phase II data show GI side effects comparable to GLP-1 agonist class. The glucagon component introduces additional theoretical concerns: - Transient heart rate increases observed in some participants - Amino acid catabolism could potentially affect lean mass preservation - Hepatic glucose output effects (mitigated by GLP-1 component in trials) - Higher discontinuation rates at the highest dose (6.0 mg) Phase III and post-marketing data will be essential for comprehensive safety characterisation. Unknown long-term effects.
The Verdict: When to Choose Which?
Choose Tirzepatide When:
- An approved, available medication is needed now — tirzepatide is accessible through prescription
- Maximum currently proven weight loss is the primary goal (~22.5% at 15 mg)
- A large evidence base with established safety and dosing provides confidence
- Type 2 diabetes management is a concurrent goal (HbA1c reductions up to 2.4%)
- Clinical experience and prescriber familiarity are valued
Choose Survodutide When:
- Metabolic-associated steatotic liver disease (MASLD/MASH) is a primary concern — survodutide's glucagon component may offer specific hepatic advantages (when approved)
- Increased resting energy expenditure is desired — glucagon's thermogenic effect is unique
- Response to GIP/GLP-1 agonism (tirzepatide) has been inadequate and a different secondary mechanism may be warranted
- Eligibility for a survodutide clinical trial with appropriate inclusion criteria
Consider Combining When:
- Combination is not applicable — both drugs include GLP-1 agonism, making co-administration pharmacologically redundant and potentially unsafe
- For patients seeking triple agonism (GIP + GLP-1 + glucagon), retatrutide is the purpose-built compound currently in Phase III trials
Frequently Asked Questions
Conclusion
Tirzepatide and survodutide exemplify the rapid evolution of multi-agonist metabolic therapy, each pairing GLP-1 agonism with a different complementary target. Tirzepatide (GIP/GLP-1) is the established leader with regulatory approval, extensive evidence, and impressive weight loss efficacy. Survodutide (GLP-1/glucagon) offers a potentially differentiated profile with glucagon-driven energy expenditure and hepatic fat oxidation that may particularly benefit patients with MASH. For current clinical use, tirzepatide is the clear evidence-based choice. Survodutide's Phase III results will determine whether glucagon co-agonism offers sufficient advantages to compete in the increasingly crowded metabolic therapy space. Both are prescription medications and should only be obtained through legitimate healthcare channels.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Tirzepatide nor Survodutide is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.